These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 36208237)

  • 1. [Effectiveness and Mechanism of Decitabine Maintenance Therapy in Patients with Medium and Low-risk Acute Myeloid Leukemia].
    Dong Y; Wang J; Tao QS; Shen YY; Zhai ZM
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Oct; 30(5):1369-1375. PubMed ID: 36208237
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical Efficacy and Survival Analysis of Adult Patients with Acute Myeloid Leukemia after Microtransplantation].
    Huang YJ; Zhang JH; Dong CX; Kang JM; Hou YF; Zhang YF; Qi K; Yang LH
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Oct; 30(5):1361-1368. PubMed ID: 36208236
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and toxicity of Decitabine in patients with acute myeloid leukemia (AML): A multicenter real-world experience.
    Filì C; Candoni A; Zannier ME; Olivieri J; Imbergamo S; Caizzi M; Nadali G; Di Bona E; Ermacora A; Gottardi M; Facchinelli D; Ciancia R; Lazzarotto D; Dubbini MV; Festini G; Gherlinzoni F; Michieli MG; Semenzato G; Fanin R
    Leuk Res; 2019 Jan; 76():33-38. PubMed ID: 30529681
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial.
    DiNardo CD; Maiti A; Rausch CR; Pemmaraju N; Naqvi K; Daver NG; Kadia TM; Borthakur G; Ohanian M; Alvarado Y; Issa GC; Montalban-Bravo G; Short NJ; Yilmaz M; Bose P; Jabbour EJ; Takahashi K; Burger JA; Garcia-Manero G; Jain N; Kornblau SM; Thompson PA; Estrov Z; Masarova L; Sasaki K; Verstovsek S; Ferrajoli A; Weirda WG; Wang SA; Konoplev S; Chen Z; Pierce SA; Ning J; Qiao W; Ravandi F; Andreeff M; Welch JS; Kantarjian HM; Konopleva MY
    Lancet Haematol; 2020 Oct; 7(10):e724-e736. PubMed ID: 32896301
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Minimal residual disease may be an early prognostic indicator for newly diagnosed acute myeloid leukemia patients induced by decitabine-based chemotherapy.
    Tan Y; Fu Y; Liu C; Sun J; Liu S; Lin H; Liu Q; Yang Y; Li Y; Su L; Gao S
    Hematology; 2019 Dec; 24(1):552-558. PubMed ID: 31315553
    [No Abstract]   [Full Text] [Related]  

  • 6. Activity of decitabine as maintenance therapy in core binding factor acute myeloid leukemia.
    Senapati J; Shoukier M; Garcia-Manero G; Wang X; Patel K; Kadia T; Ravandi F; Pemmaraju N; Ohanian M; Daver N; DiNardo C; Alvarado Y; Aldrich J; Borthakur G
    Am J Hematol; 2022 May; 97(5):574-582. PubMed ID: 35150150
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Decitabine in the Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndromes, Which Combined with Complex Karyotype Respectively.
    Gao S; Li Z; Fu JH; Hu XH; Xu Y; Jin ZM; Tang XW; Han Y; Chen SN; Sun AN; Wu DP; Qiu HY
    Asian Pac J Cancer Prev; 2015; 16(15):6627-32. PubMed ID: 26434886
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Efficacy of Decitabine Combined with Preexcitation Regimen in Treatment of Newly Diagnosed AML Patients Who Did not Respond to Initial Standard Induction Chemotherapy].
    Hou LM; Gao Y; Gao QY; Niu B
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Jun; 32(3):679-684. PubMed ID: 38926953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Efficacy and Safety of Decitabine Combined with Half-Course Pre-excitation for the Treatment of Elderly Patients with Acute Myeloid Leukemia].
    Qiu HC; Kong R; Wu PF; Wang Y; Zhang XL; Wu DH; Liu Q
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Oct; 27(5):1431-1435. PubMed ID: 31607294
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Maintenance Therapy with Decitabine after Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic Syndrome.
    Pusic I; Choi J; Fiala MA; Gao F; Holt M; Cashen AF; Vij R; Abboud CN; Stockerl-Goldstein KE; Jacoby MA; Uy GL; Westervelt P; DiPersio JF
    Biol Blood Marrow Transplant; 2015 Oct; 21(10):1761-9. PubMed ID: 26055299
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of rhG-CSF Combined With Decitabine Prophylaxis on Relapse of Patients With High-Risk MRD-Negative AML After HSCT: An Open-Label, Multicenter, Randomized Controlled Trial.
    Gao L; Zhang Y; Wang S; Kong P; Su Y; Hu J; Jiang M; Bai H; Lang T; Wang J; Liu L; Yang T; Huang X; Liu F; Lou S; Liu Y; Zhang C; Liu H; Gao L; Liu J; Zhu L; Wen Q; Chen T; Wang P; Rao J; Mao M; Wang C; Duan X; Luo L; Peng X; Cassady K; Zhong JF; Zhang X
    J Clin Oncol; 2020 Dec; 38(36):4249-4259. PubMed ID: 33108244
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.
    DiNardo CD; Pratz KW; Letai A; Jonas BA; Wei AH; Thirman M; Arellano M; Frattini MG; Kantarjian H; Popovic R; Chyla B; Xu T; Dunbar M; Agarwal SK; Humerickhouse R; Mabry M; Potluri J; Konopleva M; Pollyea DA
    Lancet Oncol; 2018 Feb; 19(2):216-228. PubMed ID: 29339097
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world experience with decitabine as a first-line treatment in 306 elderly acute myeloid leukaemia patients unfit for intensive chemotherapy.
    Bocchia M; Candoni A; Borlenghi E; Defina M; Filì C; Cattaneo C; Sammartano V; Fanin R; Sciumè M; Sicuranza A; Imbergamo S; Riva M; Fracchiolla N; Latagliata R; Caizzi E; Mazziotta F; Alunni G; Di Bona E; Crugnola M; Rossi M; Consoli U; Fontanelli G; Greco G; Nadali G; Rotondo F; Todisco E; Bigazzi C; Capochiani E; Molteni A; Bernardi M; Fumagalli M; Rondoni M; Scappini B; Ermacora A; Simonetti F; Gottardi M; Lambertenghi Deliliers D; Michieli M; Basilico C; Galeone C; Pelucchi C; Rossi G
    Hematol Oncol; 2019 Oct; 37(4):447-455. PubMed ID: 31385337
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients.
    Faderl S; Ravandi F; Huang X; Wang X; Jabbour E; Garcia-Manero G; Kadia T; Ferrajoli A; Konopleva M; Borthakur G; Burger J; Feliu J; Kantarjian HM
    Cancer; 2012 Sep; 118(18):4471-7. PubMed ID: 22282348
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial.
    Kadia TM; Cortes J; Ravandi F; Jabbour E; Konopleva M; Benton CB; Burger J; Sasaki K; Borthakur G; DiNardo CD; Pemmaraju N; Daver N; Ferrajoli A; Wang X; Patel K; Jorgensen JL; Wang S; O'Brien S; Pierce S; Tuttle C; Estrov Z; Verstovsek S; Garcia-Manero G; Kantarjian H
    Lancet Haematol; 2018 Sep; 5(9):e411-e421. PubMed ID: 30115541
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The Effects of Decitabine Combined with All-Trans Retinoic Acid on the Number of Immune Cells in Myeloid Neoplasms].
    Wei W; Liu Y; Shang LM; Cao Y; Wang F; Guo YT; Lin RR; Lin Y; Dong WM; Gu WY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Feb; 30(1):6-11. PubMed ID: 35123596
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes of newly diagnosed acute myeloid leukemia with myelodysplasia related changes and elderly acute myeloid leukemia following decitabine therapy in combination with priming regimen.
    Lai B; Mu Q; Zhang Y; Chen Y; Yan X; Ouyang G
    Hematology; 2021 Dec; 26(1):751-757. PubMed ID: 34555298
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term results of low-intensity chemotherapy with clofarabine or cladribine combined with low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia.
    Kadia TM; Ravandi F; Borthakur G; Konopleva M; DiNardo CD; Daver N; Pemmaraju N; Kanagal-Shamanna R; Wang X; Huang X; Pierce S; Rausch C; Burger J; Ferrajoli A; Jain N; Popat U; Estrov Z; Verstovsek S; Jabbour E; Garcia-Manero G; Kantarjian H
    Am J Hematol; 2021 Aug; 96(8):914-924. PubMed ID: 33901324
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Comparative analysis of decitabine combined with DAG regimen and other regimens in treatment of refractory/relapsed acute myeloid leukemia].
    Hao J; Wang L; Wang Y; Liu Z; Gu X; Liu J; Li L; Duan Y; Chen Y; Zhao W; Shen Z
    Zhonghua Xue Ye Xue Za Zhi; 2014 Jun; 35(6):481-5. PubMed ID: 24985167
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of decitabine for patients with refractory or relapsed acute myeloid leukemia: a systematic review and meta-analysis.
    Ma YY; Zhao M; Liu Y; Zhao DF; Wang LX; Chen XP; Li L
    Hematology; 2019 Dec; 24(1):507-515. PubMed ID: 31242832
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.